1029 ET - Tilray delivered a solid 3Q, says ATB's Frederico Gomes, with results meeting expectations and showing clear strength in its international cannabis business. Sales outside North America hit a record $24.1 million, up 73% year-over-year, driven mainly by growing demand in Germany. Canadian adult-use, distribution, and wellness segments also improved, but the quarter was held back by weakness in beverages, where sales fell 23.9% and margins tightened. "Despite optimism regarding international cannabis expansion, we remain overall cautious due to soft beverage industry trends and execution risks surrounding the BrewDog integration," the analyst says. ATB trims its target price to $9 from $9.50, and maintains a sector perform rating on the stock. (adriano.marchese@wsj.com)
(END) Dow Jones Newswires
April 02, 2026 10:29 ET (14:29 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.